Clinical meaning
Brainstem gliomas are a heterogeneous group of central nervous system tumors arising within the brainstem (midbrain, pons, or medulla oblongata). They represent approximately 10-20% of all pediatric brain tumors and 1-2% of adult brain tumors, with a peak incidence between ages 5-10 years. The brainstem is among the most critical anatomical structures in the central nervous system, serving as the conduit for all motor and sensory pathways between the cerebral hemispheres and the spinal cord, housing the cranial nerve nuclei (III through XII), and containing the vital centers that regulate consciousness (reticular activating system), respiration (dorsal and ventral respiratory groups in the medulla), cardiovascular function (vasomotor center, cardiac centers), and autonomic nervous system activity. The critical functional density of the brainstem means that even small tumors can produce devastating neurological deficits, and surgical resection is often impossible without causing unacceptable morbidity. Brainstem gliomas are classified by their growth pattern, location, and histology, which are the primary determinants of prognosis and treatment approach. Diffuse intrinsic pontine glioma (DIPG), now reclassified as diffuse midline glioma H3K27-altered in the WHO 2021 classification, is the most common and most devastating subtype, accounting for approximately 75-80% of pediatric brainstem gliomas. DIPG arises diffusely within the pons, infiltrating between and around normal neural structures rather than displacing them, making surgical resection impossible. Histologically, DIPG typically demonstrates high-grade astrocytic features (WHO grade III or IV), and the defining molecular alteration is a lysine-to-methionine substitution at position 27 of the histone H3 protein (H3K27M mutation), found in approximately 80% of DIPGs. This histone mutation has profound epigenetic consequences: the mutant H3K27M protein acts as a dominant-negative inhibitor of the Polycomb Repressive Complex 2 (PRC2), a key epigenetic regulator that normally trimethylates H3K27 (H3K27me3) to silence gene expression. Loss of H3K27me3 leads to global epigenetic reprogramming with widespread de-repression of genes that promote cell proliferation, stem cell maintenance, and resistance to differentiation and apoptosis. The result is a highly proliferative, treatment-resistant tumor with a median survival of only 9-11 months from diagnosis. The prognosis for DIPG remains among the worst of any pediatric malignancy, with less than 10% survival at 2 years. Focal brainstem gliomas, in contrast, are well-circumscribed tumors that grow as discrete masses, often exophytic (growing outward from the brainstem surface into the surrounding CSF spaces). These are typically low-grade (WHO grade I or II) pilocytic astrocytomas or gangliogliomas, most commonly arising in the midbrain tectum (tectal gliomas) or the cervicomedullary junction. Because they are well-demarcated from surrounding brain tissue, focal brainstem gliomas may be amenable to surgical resection or debulking, and many behave indolently with prolonged survival. Tectal gliomas, in particular, often present with obstructive hydrocephalus (due to compression of the cerebral aqueduct) and may remain stable for years after CSF diversion alone, sometimes never requiring tumor-directed therapy. The clinical presentation of brainstem gliomas depends on the specific location within the brainstem and the cranial nerve nuclei and long tracts affected. The classic triad of DIPG presentation includes cranial nerve palsies (especially CN VI causing lateral rectus palsy with diplopia and CN VII causing facial weakness), long tract signs (hemiparesis or quadriparesis from corticospinal tract involvement, hyperreflexia, positive Babinski sign), and cerebellar signs (ataxia, dysmetria, intention tremor from involvement of cerebellar peduncles). Symptoms typically develop rapidly over weeks (consistent with the aggressive growth of DIPG), in contrast to the more insidious presentation of low-grade focal tumors. Additional presenting symptoms may include headache and vomiting (from hydrocephalus caused by CSF pathway obstruction), swallowing difficulties and dysarthria (from lower cranial nerve involvement), respiratory irregularities (Cheyne-Stokes respiration, apneic episodes from medullary respiratory center involvement), and hearing loss (from CN VIII involvement). The diagnosis of brainstem gliomas relies primarily on MRI findings. DIPG characteristically appears as a diffuse, expansile, T2/FLAIR hyperintense mass centered in the pons, enlarging the pons to more than twice its normal anteroposterior diameter, often with ventral encasement of the basilar artery and extension into adjacent structures (midbrain, medulla, cerebellar peduncles). The MRI appearance is considered sufficiently diagnostic that tissue biopsy has historically not been required for DIPG -- although stereotactic biopsy is increasingly performed to confirm H3K27M mutation status and identify potential molecular targets for clinical trials. Treatment of DIPG remains limited: radiation therapy (conventional fractionated radiation to 54-59.4 Gy over 6 weeks) is the only treatment demonstrated to provide temporary clinical improvement and modest survival prolongation (median survival improvement from 5 months to 9-11 months), but the tumor invariably recurs. No chemotherapy regimen has shown significant survival benefit for DIPG in randomized trials. For focal brainstem gliomas, management depends on histology and resectability: surgical resection is performed when safe, and observation with serial MRI is appropriate for indolent lesions (particularly tectal gliomas after CSF diversion). Chemotherapy (carboplatin/vincristine) is used for progressive low-grade tumors, and radiation therapy is reserved for unresectable or progressive tumors. The nurse caring for patients with brainstem gliomas must perform meticulous neurological assessments (including cranial nerve function, motor strength, cerebellar testing, level of consciousness, and vital sign monitoring for brainstem compression), manage complications (aspiration risk from swallowing dysfunction, respiratory compromise, increased intracranial pressure), provide supportive care during radiation therapy (managing fatigue, skin care, steroid side effects), and offer compassionate psychosocial support to families facing a devastating diagnosis, particularly in the pediatric population.